{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT06445062","nct_id":"NCT06445062","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06445062. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"RMC-6236 (QD) and bevacizumab with 5-fluorouracil-based regimens","label":"Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC","type":"EXPERIMENTAL"},{"description":"RMC-6236 (QD) and cetuximab with or without mFOLFOX6","label":"Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDAC","type":"EXPERIMENTAL"},{"description":"RMC-6236 (QD) and gemcitabine with nab-paclitaxel","label":"Subprotocol C: metastatic PDAC","type":"EXPERIMENTAL"},{"description":"RMC-9805 (QD or BID) with or without RMC-6236 (QD), and bevacizumab with 5-fluorouracil- based regimens","label":"Subprotocol D: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC","type":"EXPERIMENTAL"},{"description":"RMC-9805 (QD or BID) with or without RMC-6236 (QD), and cetuximab with or without mFOLFOX6","label":"Subprotocol E: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC","type":"EXPERIMENTAL"},{"description":"RMC-9805 (QD or BID) with or without RMC-6236 (QD), and gemcitabine with nab-paclitaxel","label":"Subprotocol F: RAS G12D-mutated metastatic PDAC","type":"EXPERIMENTAL"},{"description":"RMC-9805 (QD) and cetuximab with FOLFIRI","label":"Subprotocol G: RAS G12D-mutated metastatic CRC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-03-30","type":"ESTIMATED"},"conditions":["Colorectal Cancer","CRC","Pancreatic Ductal Adenocarcinoma","PDAC","Gastrointestinal Cancer","Metastatic Pancreatic Ductal Adenocarcinoma"],"enrollment":{"count":1130,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"RMC-6236","type":"DRUG"},{"name":"mFOLFOX6 regimen","type":"DRUG"},{"name":"bevacizumab","type":"DRUG"},{"name":"mFOLFIRINOX regimen","type":"DRUG"},{"name":"cetuximab","type":"DRUG"},{"name":"gemcitabine","type":"DRUG"},{"name":"nab-paclitaxel","type":"DRUG"},{"name":"RMC-9805","type":"DRUG"},{"name":"FOLFIRI regimen","type":"DRUG"}],"last_update":"2026-09-22","lead_sponsor":"Revolution Medicines, Inc.","official_title":"A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-09-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Adverse events (Subprotocols A-F)","timeFrame":"Up to 3 years"},{"measure":"Dose limiting toxicities (Subprotocols A-F)","timeFrame":"28 days"},{"measure":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)","timeFrame":"Up to 3 years"}],"references":[{"citation":"Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, Marquez A, Liu Y, Freilich R, Aay N, Wang Y, Jiang L, Jiang J, Wang Z, Flagella M, Wildes D, Smith JAM, Singh M, Wang Z, Gill AL, Koltun ES. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8.","pmid":"40056080","type":"DERIVED"}],"start_date":{"date":"2024-05-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06445062"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06445062"}